Evergreen Discovery has partnered with Orbit Discovery to discover specific cell-targeting peptides and advance the development of new radiopharmaceuticals.

Both firms will focus on creating peptide libraries, as well as hit identification and hit validation to verify cell surface-binding properties.

The partnership will involve the use of Orbit’s peptide display technologies to identify peptide leads which are specific to tumour-related targets.

The Orbit platform will also conduct in vitro transcription conversion from DNA-encoded libraries on beads.

This enables the screening of vast libraries, by employing fluorescence-activated cell sorting (FACS)-based methodologies.

In addition, Evergreen will support the development of the peptides for use in clinical environments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Evergreen Discovery chief scientific officer Dr Thomas Reiner said: “We are very pleased to be partnering with Orbit Discovery and capitalising on its technology and expertise in both chemistry and biology to drive innovation and expansion of our radiopharmaceutical candidate pipeline.

“The requirement for more direct screening technologies is key to successful drug development, and we see Orbit as a stepping stone in attaining our goals in a rapid timeframe.”

The latest collaboration aims to tap the expanding radiopharmaceuticals industry, which has seen the development of a number of targeting moieties.

These moieties are capable of enabling specific binding to a tumour target, with the ability to localise the treatment to diseased tissues.

Peptides are considered to be an important delivery method as they have the capability to minimise off-target toxicities.